Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine

Molecular Carcinogenesis

Volumn 42, Issue 3, 2005, Pages 142-149

  Dunois Lardé, Claire ^a   Levrel, Olivier ^b   Brams, Aude ^a   Thiery, Jean Paul ^a   Radvanyi, François ^a  

^a CNRS   (France)

^b Ctr d'Anatomie et Cytologie Pathol   (France)

Author keywords

Fibroblast growth factor receptor 3; Mouse; Mutations; Rat; Urothelial cell carcinomas

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; URINARY TRACT CARCINOMA; UROTHELIUM;

ANIMALS; BASE SEQUENCE; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOMA; DNA, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTAGENS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; RATS; RATS, INBRED F344; RATS, WISTAR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; URINARY BLADDER NEOPLASMS;

ANIMALIA;

EID: 13944279602     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20075     Document Type: Article

References (32)

1. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000;27:1-13, vii.
2. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 1993; 11:177-192.
3. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788.
4. Cordon-Cardo C. Molecular alterations in bladder cancer. Cancer Surv 1998;32:115-131.
5. Knowles MA. The genetics of transitional cell carcinoma: Progress and potential clinical application. BJU Int 1999; 84:412-427.
6. Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer 1997;19:84-89.
7. Hartmann A, Zanardo L, Bocker-Edmonston T, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 2002;62:6796-6802.
8. Wagner U, Sauter G, Moch H, et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995;26:970-978.
9. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002;161:1119-1125.
10. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. Faseb J 1995; 9:919-925.
11. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60:1-41.
12. Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, et al. Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev 1998;77:19-30.
13. Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK. Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 1994;54:5206-5211.
14. Claus P, Grothe C. Molecular cloning and developmental expression of rat fibroblast growth factor receptor 3. Histochem Cell Biol 2001;115:147-155.
15. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-1465.
16. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-264.
17. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997;90:4062-4070.
18. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
19. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-1959.
20. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001;92:2555-2561.
21. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-1268.
22. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001;20:686-691.
23. el-Marjou A, Delouvee A, Thiery JP, Radvanyi F. Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis 2000; 21:2211-2218.
24. Fukushima S, Hirose M, Tsuda H, Shirai T, Hirao K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann 1976;67:81-90.
25. Ohtani M, Kakizoe T, Nishio Y, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4- hydroxybutyl)nitrosamine. Cancer Res 1986;46:2001-2004.
26. Herman CJ, Vegt PD, Debruyne FM, Vooijs GP, Ramaekers FC. Squamous and transitional elements in rat bladder carcinomas induced by N-butyl-N-4- hydroxybutyl-nitrosamine (BBN). A study of cytokeratin expression. Am J Pathol 1985;120:419-426.
27. Toyoshima K, Ito N, Hiasa Y, Kamamoto Y, Makiura S. Tissue culture of urinary bladder tumor induced in a rat by N-butyl-N-(-4-hydroxybutyl) nitrosamine: Establishment of cell line, Nara Bladder Tumor II. J Natl Cancer Inst 1971;47:979-985.
28. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours. Vol. 10. Geneva: World Health Organization; 1973.pp21-31.
29. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn. (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-1804.
30. Shiina H, Igawa M, Urakami S, et al. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer. Cancer Res 2001;61:7101-7109.
31. Yamamoto S, Masui T, Murai T, et al. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1995; 16:2363-2368.
32. Masui T, Dong Y, Yamamoto S, et al. p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4- hydroxybutyl)-nitrosamine. Cancer Lett 1996;105:105-112.